**Background of C9orf72 Antibodies**
C9orf72 antibodies are immunological tools designed to detect the protein product of the *C9orf72* gene, which is implicated in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The *C9orf72* gene contains a hexanucleotide repeat expansion (GGGGCC) in its non-coding region, which is the most common genetic cause of familial ALS and FTD. This mutation leads to loss of functional C9orf72 protein, toxic RNA foci, and dipeptide repeat proteins (DPRs) through repeat-associated non-AUG (RAN) translation.
C9orf72 antibodies are primarily used in research to study the gene’s normal physiological role and disease mechanisms. They target specific regions of the C9orf72 protein, such as its isoforms or pathological aggregates. For example, some antibodies detect endogenous C9orf72 in human tissues, while others recognize DPRs like poly-GA, poly-GP, or poly-PR. These tools help elucidate how C9orf72 loss-of-function or gain-of-toxic-function contributes to neuronal degeneration.
Challenges in antibody development include the low abundance of C9orf72 protein in cells and the heterogeneity of pathological aggregates. Commercially available antibodies vary in specificity, requiring validation via knockout controls or epitope mapping. While C9orf72 antibodies are critical for preclinical studies, their diagnostic utility remains limited, as clinical diagnosis still relies on genetic testing for the repeat expansion. Ongoing research aims to refine these antibodies for therapeutic targeting or biomarker development.